Another interesting trial is the KEYSTEP-008, which is investigating pembrolizumab in combination with different checkpoint inhibitors (CTLA-4, LAG-3, TIGIT and ILT-4) in patients with MSI-H CRC [58]. This evidence concerns the gene CTLA4 and colorectal carcinoma.